University of Texas MD Anderson Cancer Center

Our News on Newswise
View All >

MD Anderson Research Highlights for December 18, 2024

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚...
18-Dec-2024 10:15 PM EST Add to Favorites

Newswise: 675368b210ae9_119917ByersL.jpg

MD Anderson鈥檚 Lauren Averett Byers Receives TAMEST O鈥橠onnell Award for Seminal Contributions to Lung Cancer Research

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, has received the 2025 Edith and Peter O鈥橠onnell Award in Medicine from the Texas Academy of Medicine, Engineering,...
11-Dec-2024 8:00 AM EST Add to Favorites

MD Anderson and AmMax Bio Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

MD Anderson and AmMax Bio announced agreements to develop and advance AmMax's AMB-066 monoclonal antibody therapy for colorectal cancer with minimal residual disease.
10-Dec-2024 8:00 AM EST Add to Favorites

ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The...
9-Dec-2024 8:00 PM EST Add to Favorites

ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory Disorder

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) 鈥� a rare, aggressive hyperinflammatory condition 鈥� who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100%...
9-Dec-2024 5:45 PM EST Add to Favorites

MD Anderson Research Highlights: ASH 2024 Special Edition

Novel CAR TCell Therapy Obe-Cel Demonstrates High Response Rates in Adult Patients with Advanced B-Cell ALL

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates...
27-Nov-2024 5:05 PM EST Add to Favorites

MD Anderson Research Highlights for November 21, 2024

See All News

Our Experts on Newswise

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country鈥檚 health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

AUDIO

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

AUDIO

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

See All Experts

Our YouTube Videos
View All >

About

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution鈥檚 sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation鈥檚 first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report鈥檚鈥淏est Hospitals鈥� rankings and has been named one of the nation鈥檚 top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).